Effect of MD1003 in Spinal Progressive Multiple Sclerosis

Summary

The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.

Timeline

Start

2013-10

Primary completion

2016-01

Completion

2018-01

Drugs

Indications